The week in pharma: action, reaction and insight – week to September 22, 2023

24 September 2023
tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Editor

Regulatory news last week included the US Food and Drug Administration a(FDA) approving UK pharma major GSK’s new myelofibrosis drug Ojjaara (momelotinib) with a wider indication than what hade been expected. The US Federal Commission (FTC) issued a policy on the listing of patents in the FDA’S Orange Book. Last Tuesday, Chinese biotech BeiGene revealed that Swiss pharma giant Novartis has pulled out of a second collaboration, this time regarding time regarding Tevimbra (tislelizumab). Also of note on the research front, US CNS specialist Relmada Therapeutics released positive Phase III results for its REL-1017 as a treatment for major depressive disorder (MDD).

GSK’s Ojjaara approval in MF with anemia; line-agnostic label could dent Jakafi’s hold

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology